With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, regulatory change is accelerating, solidifying Model-Informed Drug Development (MIDD) as a critical, non-negotiable tool in the drug development process.

The Model-Informed Drug Development Summit is the first and only industry-focused, 3-day strategic meeting dedicated to exploring how MIDD is transforming decision-making and driving drug development success. This is your opportunity to benchmark against industry leaders, refine your strategy, and future-proof your development approach.

Join senior experts in pharmacometrics, clinical pharmacology, PK/PD, and modeling from leading organizations including Pfizer, Third Rock Ventures, Johnson & Johnson, AbbVie, and more, as they uncover how MIDD is being used to:

• Select better candidates earlier in development
• Streamline or eliminate clinical trial phases
• Personalize and optimize trial designs
• Build stronger, data-driven regulatory submissions

Why Attend?

• Unlock real-world case studies showing how MIDD accelerates timelines, cuts costs, and improves outcomes
• Gain insight into how peers are implementing MIDD from discovery through to regulatory approval
• Collaborate with cross-functional teams to exchange strategies and overcome shared challenges

With exclusive insights into ICH M15, practical applications across diverse therapeutic areas, and proven examples of success, this summit is your one-stop shop for unleashing the full potential of MIDD.

Learn more here: https://ter.li/unljt8